Engineered Herpes Viruses Show Modest but Meaningful Gains Against Solid Tumors
A meta-analysis of 38 clinical trials finds oncolytic herpes simplex virus therapy delivers modest anti-tumor activity across solid tumors, with ...
A meta-analysis of 38 clinical trials finds oncolytic herpes simplex virus therapy delivers modest anti-tumor activity across solid tumors, with ...
A new Perspective argues that next-generation oncolytic viruses act as antigen-agnostic in situ vaccines capable of priming de novo antitumor ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine